Please use this identifier to cite or link to this item:
|Title:||Effect of Maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals|
Llibre, Josep María
Puertas, Maria C.
Martínez Picado, Francisco Javier
Miró Meda, José M.
Pozniak, Anton L.
Gatell, José M.
Clotet i Sala, Bonaventura
|Publisher:||Public Library of Science (PLoS)|
|Abstract:||BACKGROUND: The effect of maraviroc on the maintenance and the function of HIV-1-specific T cell responses remains unknown. METHODS: Subjects recently infected with HIV-1 were randomized to receive anti-retroviral treatment with or without maraviroc intensification for 48 weeks, and were monitored up to week 60. PBMC and in vitro-expanded T cells were tested for responses to the entire HIV proteome by ELISpot analyses. Intracellular cytokine staining assays were conducted to monitor the (poly)-functionality of HIV-1-specific T cells. Analyses were performed at baseline and week 24 after treatment start, and at week 60 (3 months after maraviroc discontinuation). RESULTS: Maraviroc intensification was associated with a slower decay of virus-specific T cell responses over time compared to the non-intensified regimen in both direct ex-vivo as well as in in-vitro expanded cells. The effector function profiles of virus-specific CD8⁺ T cells were indistinguishable between the two arms and did not change over time between the groups. CONCLUSIONS: Maraviroc did not negatively impact any of the measured parameters, but was rather associated with a prolonged maintenance of HIV-1-specific T cell responses. Maraviroc, in addition to its original effect as viral entry inhibitor, may provide an additional benefit on the maintenance of virus-specific T cells which may be especially important for future viral eradication strategies.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0087334|
|It is part of:||PLoS One, 2014, vol. 9, num. 1, p. e87334|
|Appears in Collections:||Articles publicats en revistes (Medicina)|
This item is licensed under a Creative Commons License